Skip to main content
Top
Published in: Immunity & Ageing 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Research

Immune profiles of pre-frail people living with HIV-1: a prospective longitudinal study

Authors: Lucy Kundura, Renaud Cezar, Sandrine Gimenez, Manuela Pastore, Christelle Reynes, Albert Sotto, Jacques Reynes, Clotilde Allavena, Laurence Meyer, Alain Makinson, Pierre Corbeau

Published in: Immunity & Ageing | Issue 1/2024

Login to get access

Abstract

Background

People living with HIV (PLWH) are at risk of frailty, which is predictive for death. As an overactivity of the immune system is thought to fuel frailty, we characterized the immune activation profiles linked to frailty.

Methods

We quantified twenty-seven activation markers in forty-six virological responders (four females and forty-two males; median age, 74 years; median duration of infection, 24 years; median duration of undetectability, 13 years), whose frailty was determined according to the Fried criteria. T cell and NK cell activation was evaluated by flow cytometry, using a panel of cell surface markers. Soluble markers of inflammation, and monocyte activation and endothelial activation were measured by ELISA. The participants’ immune activation was profiled by an unsupervised double hierarchical clustering analysis. We used ANOVA p-values to rank immunomarkers most related to Fried score. A Linear Discriminant Analysis (LDA) was performed to link immune activation markers to frailty.

Results

41% of the participants were pre-frail, including 24% with a Fried score of 1, and 17% with a Fried score of 2. ANOVA identified the 14 markers of T cell, monocyte, NK cell, endothelial activation, and inflammation the most linked to Fried 3 classes. The LDA performed with these 14 markers was capable of discriminating volunteers according to their Fried score. Two out of the 5 immune activation profiles revealed by the hierarchical clustering were linked to and predictive of pre-frailty. These two profiles were characterized by a low percentage of CD4 T cells and a high percentage of CD8 T cells, activated CD4 T cells, CD8 T cells, and NK cells, and inflammation.

Conclusions

We identified a particular immune activation profile associated with pre-frailty in PLWH. Profiling participants at risk of developing frailty might help to tailor the screening and prevention of medical complications fueled by loss of robustness. Further studies will indicate whether this frailty signature is specific or not of HIV infection, and whether it also precedes frailty in the general population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Biol Sci Med Sci. 2001;56(3):M146–56.CrossRef Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Biol Sci Med Sci. 2001;56(3):M146–56.CrossRef
2.
go back to reference Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016;30(2):241–50.PubMedCrossRef Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016;30(2):241–50.PubMedCrossRef
3.
go back to reference Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–94.PubMedPubMedCentralCrossRef Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–94.PubMedPubMedCentralCrossRef
4.
go back to reference Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS. 2015;29(13):1633–41.PubMedCrossRef Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS. 2015;29(13):1633–41.PubMedCrossRef
5.
go back to reference Allavena C, Blain H, Abulizi X, Slama L, Katlama C, Delobel P, et al. Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older. AIDS. 2023;37(1):183–9.PubMedCrossRef Allavena C, Blain H, Abulizi X, Slama L, Katlama C, Delobel P, et al. Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older. AIDS. 2023;37(1):183–9.PubMedCrossRef
6.
go back to reference Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol Biol Sci Med Sci. 2014;69(2):189–98.CrossRef Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol Biol Sci Med Sci. 2014;69(2):189–98.CrossRef
7.
go back to reference Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249–59.PubMedPubMedCentralCrossRef Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249–59.PubMedPubMedCentralCrossRef
8.
go back to reference Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59(5):346–52.PubMedCrossRef Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59(5):346–52.PubMedCrossRef
9.
go back to reference Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS ONE. 2013;8(1):e54910.ADSPubMedPubMedCentralCrossRef Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS ONE. 2013;8(1):e54910.ADSPubMedPubMedCentralCrossRef
10.
go back to reference Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012;13(6):324–34.PubMedPubMedCentralCrossRef Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012;13(6):324–34.PubMedPubMedCentralCrossRef
11.
go back to reference Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt). 2009;18(12):1965–74.PubMedCrossRef Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt). 2009;18(12):1965–74.PubMedCrossRef
12.
go back to reference Yeoh HL, Cheng AC, Cherry CL, Weir JM, Meikle PJ, Hoy JF, et al. Immunometabolic and lipidomic markers Associated with the Frailty Index and Quality of Life in Aging HIV + Men on antiretroviral therapy. EBioMedicine. 2017;22:112–21.PubMedPubMedCentralCrossRef Yeoh HL, Cheng AC, Cherry CL, Weir JM, Meikle PJ, Hoy JF, et al. Immunometabolic and lipidomic markers Associated with the Frailty Index and Quality of Life in Aging HIV + Men on antiretroviral therapy. EBioMedicine. 2017;22:112–21.PubMedPubMedCentralCrossRef
13.
go back to reference Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr. 2013;63(2):209–15.PubMedPubMedCentralCrossRef Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr. 2013;63(2):209–15.PubMedPubMedCentralCrossRef
14.
go back to reference Masters MC, Perez J, Wu K, Ellis RJ, Goodkin K, Koletar SL, et al. Baseline neurocognitive impairment (NCI) is Associated With Incident Frailty but Baseline Frailty does not Predict Incident NCI in older persons with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021;73(4):680–8.PubMedPubMedCentralCrossRef Masters MC, Perez J, Wu K, Ellis RJ, Goodkin K, Koletar SL, et al. Baseline neurocognitive impairment (NCI) is Associated With Incident Frailty but Baseline Frailty does not Predict Incident NCI in older persons with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021;73(4):680–8.PubMedPubMedCentralCrossRef
15.
go back to reference Ianas V, Berg E, Mohler MJ, Wendel C, Klotz SA. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care. 2013;12(1):62–6.PubMedCrossRef Ianas V, Berg E, Mohler MJ, Wendel C, Klotz SA. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care. 2013;12(1):62–6.PubMedCrossRef
16.
go back to reference Pathai S, Gilbert C, Weiss HA, Cook C, Wood R, Bekker LG, et al. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr. 2013;62(1):43–51.PubMedPubMedCentralCrossRef Pathai S, Gilbert C, Weiss HA, Cook C, Wood R, Bekker LG, et al. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr. 2013;62(1):43–51.PubMedPubMedCentralCrossRef
17.
go back to reference Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018;40:17–35.PubMedCrossRef Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018;40:17–35.PubMedCrossRef
18.
go back to reference Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 2007;7:212.PubMedPubMedCentralCrossRef Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 2007;7:212.PubMedPubMedCentralCrossRef
19.
go back to reference Halaris A. Co-morbidity between cardiovascular pathology and depression: role of inflammation. Mod Trends Pharmacopsychiatry. 2013;28:144–61.PubMedCrossRef Halaris A. Co-morbidity between cardiovascular pathology and depression: role of inflammation. Mod Trends Pharmacopsychiatry. 2013;28:144–61.PubMedCrossRef
20.
go back to reference Younas M, Psomas C, Reynes J, Corbeau P. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med. 2016;17:89–105.PubMedCrossRef Younas M, Psomas C, Reynes J, Corbeau P. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med. 2016;17:89–105.PubMedCrossRef
21.
go back to reference Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV + and HIV- Men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2017;74(4):407–17.PubMedPubMedCentralCrossRef Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV + and HIV- Men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2017;74(4):407–17.PubMedPubMedCentralCrossRef
22.
go back to reference Piggott DA, Varadhan R, Mehta SH, Brown TT, Li H, Walston JD, et al. Frailty, inflammation, and Mortality among persons Aging with HIV infection and Injection Drug Use. J Gerontol Biol Sci Med Sci. 2015;70(12):1542–7.CrossRef Piggott DA, Varadhan R, Mehta SH, Brown TT, Li H, Walston JD, et al. Frailty, inflammation, and Mortality among persons Aging with HIV infection and Injection Drug Use. J Gerontol Biol Sci Med Sci. 2015;70(12):1542–7.CrossRef
23.
go back to reference Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50(7):1268–71.PubMedCrossRef Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50(7):1268–71.PubMedCrossRef
24.
go back to reference Margolick JB, Bream JH, Nilles TL, Li H, Langan SJ, Deng S, et al. Relationship between T-Cell responses to CMV, markers of inflammation, and Frailty in HIV-uninfected and HIV-infected men in the Multicenter AIDS Cohort Study. J Infect Dis. 2018;218(2):249–58.PubMedPubMedCentralCrossRef Margolick JB, Bream JH, Nilles TL, Li H, Langan SJ, Deng S, et al. Relationship between T-Cell responses to CMV, markers of inflammation, and Frailty in HIV-uninfected and HIV-infected men in the Multicenter AIDS Cohort Study. J Infect Dis. 2018;218(2):249–58.PubMedPubMedCentralCrossRef
25.
go back to reference Derry HM, Johnston CD, Burchett CO, Brennan-Ing M, Karpiak S, Zhu YS, et al. Links between inflammation, Mood, and physical function among older adults with HIV. J Gerontol B Psychol Sci Soc Sci. 2022;77(1):50–60.PubMedCrossRef Derry HM, Johnston CD, Burchett CO, Brennan-Ing M, Karpiak S, Zhu YS, et al. Links between inflammation, Mood, and physical function among older adults with HIV. J Gerontol B Psychol Sci Soc Sci. 2022;77(1):50–60.PubMedCrossRef
26.
go back to reference Hamilton GF, McDonald C, Chenier TC. Measurement of grip strength: validity and reliability of the sphygmomanometer and jamar grip dynamometer. J Orthop Sports Phys Ther. 1992;16(5):215–9.PubMedCrossRef Hamilton GF, McDonald C, Chenier TC. Measurement of grip strength: validity and reliability of the sphygmomanometer and jamar grip dynamometer. J Orthop Sports Phys Ther. 1992;16(5):215–9.PubMedCrossRef
27.
go back to reference Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115.PubMedPubMedCentralCrossRef Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115.PubMedPubMedCentralCrossRef
28.
go back to reference Raho-Moussa M, Guiguet M, Michaud C, Honore P, Palacios C, Boue F, et al. Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France. PLoS ONE. 2019;14(3):e0213019.PubMedPubMedCentralCrossRef Raho-Moussa M, Guiguet M, Michaud C, Honore P, Palacios C, Boue F, et al. Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France. PLoS ONE. 2019;14(3):e0213019.PubMedPubMedCentralCrossRef
29.
go back to reference Cezar R, Winter A, Desigaud D, Pastore M, Kundura L, Dupuy A-M, et al. Identification of distinct immune activation profiles in adult humans. Sci Rep. 2020;10(1):20824.PubMedPubMedCentralCrossRef Cezar R, Winter A, Desigaud D, Pastore M, Kundura L, Dupuy A-M, et al. Identification of distinct immune activation profiles in adult humans. Sci Rep. 2020;10(1):20824.PubMedPubMedCentralCrossRef
30.
go back to reference Cezar R, Desigaud D, Pastore M, Kundura L, Dupuy AM, Cognot C, et al. Insulin resistance is linked to a specific profile of immune activation in human subjects. Sci Rep. 2021;11(1):12314.PubMedPubMedCentralCrossRef Cezar R, Desigaud D, Pastore M, Kundura L, Dupuy AM, Cognot C, et al. Insulin resistance is linked to a specific profile of immune activation in human subjects. Sci Rep. 2021;11(1):12314.PubMedPubMedCentralCrossRef
31.
go back to reference Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8.PubMedCrossRef Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8.PubMedCrossRef
32.
go back to reference Puzianowska-Kuznicka M, Owczarz M, Wieczorowska-Tobis K, Nadrowski P, Chudek J, Slusarczyk P, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Ageing. 2016;13:21.PubMedPubMedCentralCrossRef Puzianowska-Kuznicka M, Owczarz M, Wieczorowska-Tobis K, Nadrowski P, Chudek J, Slusarczyk P, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Ageing. 2016;13:21.PubMedPubMedCentralCrossRef
33.
go back to reference Walker KA, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Windham BG, et al. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. Neurology. 2017;89(22):2262–70.PubMedPubMedCentralCrossRef Walker KA, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Windham BG, et al. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. Neurology. 2017;89(22):2262–70.PubMedPubMedCentralCrossRef
34.
go back to reference De Fanis U, Wang GC, Fedarko NS, Walston JD, Casolaro V, Leng SX. T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. J Am Geriatr Soc. 2008;56(5):904–8.PubMedPubMedCentralCrossRef De Fanis U, Wang GC, Fedarko NS, Walston JD, Casolaro V, Leng SX. T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. J Am Geriatr Soc. 2008;56(5):904–8.PubMedPubMedCentralCrossRef
36.
go back to reference Johnstone J, Parsons R, Botelho F, Millar J, McNeil S, Fulop T, et al. T-Cell phenotypes predictive of Frailty and Mortality in Elderly nursing home residents. J Am Geriatr Soc. 2017;65(1):153–9.PubMedCrossRef Johnstone J, Parsons R, Botelho F, Millar J, McNeil S, Fulop T, et al. T-Cell phenotypes predictive of Frailty and Mortality in Elderly nursing home residents. J Am Geriatr Soc. 2017;65(1):153–9.PubMedCrossRef
37.
go back to reference Rodriguez IJ, Lalinde Ruiz N, Llano Leon M, Martinez Enriquez L, Montilla Velasquez MDP, Ortiz Aguirre JP, et al. Immunosenescence Study of T Cells: a systematic review. Front Immunol. 2020;11:604591.PubMedCrossRef Rodriguez IJ, Lalinde Ruiz N, Llano Leon M, Martinez Enriquez L, Montilla Velasquez MDP, Ortiz Aguirre JP, et al. Immunosenescence Study of T Cells: a systematic review. Front Immunol. 2020;11:604591.PubMedCrossRef
38.
go back to reference Leng SX, Tian X, Matteini A, Li H, Hughes J, Jain A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing. 2011;40(4):475–81.PubMedPubMedCentralCrossRef Leng SX, Tian X, Matteini A, Li H, Hughes J, Jain A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing. 2011;40(4):475–81.PubMedPubMedCentralCrossRef
39.
go back to reference Chhetri JK, de Souto Barreto P, Fougere B, Rolland Y, Vellas B, Cesari M. Chronic inflammation and sarcopenia: a regenerative cell therapy perspective. Exp Gerontol. 2018;103:115–23.PubMedCrossRef Chhetri JK, de Souto Barreto P, Fougere B, Rolland Y, Vellas B, Cesari M. Chronic inflammation and sarcopenia: a regenerative cell therapy perspective. Exp Gerontol. 2018;103:115–23.PubMedCrossRef
40.
go back to reference Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentralCrossRef Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentralCrossRef
41.
go back to reference Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res. 1993;12(4):219–23.PubMed Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res. 1993;12(4):219–23.PubMed
42.
go back to reference Borsini A, Cattaneo A, Malpighi C, Thuret S, Harrison NA, Consortium MRCI, et al. Interferon-Alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-Dependent mechanisms. Int J Neuropsychopharmacol. 2018;21(2):187–200.PubMedCrossRef Borsini A, Cattaneo A, Malpighi C, Thuret S, Harrison NA, Consortium MRCI, et al. Interferon-Alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-Dependent mechanisms. Int J Neuropsychopharmacol. 2018;21(2):187–200.PubMedCrossRef
43.
44.
go back to reference Schmeer C, Kretz A, Wengerodt D, Stojiljkovic M, Witte OW. Dissecting aging and senescence-current concepts and Open lessons. Cells. 2019;8(11). Schmeer C, Kretz A, Wengerodt D, Stojiljkovic M, Witte OW. Dissecting aging and senescence-current concepts and Open lessons. Cells. 2019;8(11).
45.
go back to reference Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, et al. One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: the ACTIVIH study. EBioMedicine. 2016;8:265–76.PubMedPubMedCentralCrossRef Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, et al. One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: the ACTIVIH study. EBioMedicine. 2016;8:265–76.PubMedPubMedCentralCrossRef
46.
go back to reference Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323–e32.PubMedPubMedCentralCrossRef Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323–e32.PubMedPubMedCentralCrossRef
Metadata
Title
Immune profiles of pre-frail people living with HIV-1: a prospective longitudinal study
Authors
Lucy Kundura
Renaud Cezar
Sandrine Gimenez
Manuela Pastore
Christelle Reynes
Albert Sotto
Jacques Reynes
Clotilde Allavena
Laurence Meyer
Alain Makinson
Pierre Corbeau
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2024
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-024-00416-5

Other articles of this Issue 1/2024

Immunity & Ageing 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine